Marshall & Sullivan’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-2,450
Closed -$194K 78
2025
Q2
$194K Hold
2,450
0.09% 45
2025
Q1
$220K Hold
2,450
0.11% 42
2024
Q4
$244K Hold
2,450
0.12% 40
2024
Q3
$278K Hold
2,450
0.13% 37
2024
Q2
$303K Hold
2,450
0.15% 36
2024
Q1
$323K Hold
2,450
0.16% 36
2023
Q4
$267K Hold
2,450
0.14% 38
2023
Q3
$252K Hold
2,450
0.15% 37
2023
Q2
$283K Hold
2,450
0.16% 38
2023
Q1
$261K Hold
2,450
0.16% 38
2022
Q4
$272K Hold
2,450
0.17% 36
2022
Q3
$210K Hold
2,450
0.15% 35
2022
Q2
$223K Hold
2,450
0.14% 37
2022
Q1
$201K Buy
+2,450
New +$193K 0.11% 37
2021
Q1
Sell
-210
Closed -$2.45K 50
2020
Q4
$2.45K Sell
210
-2,358
-92% -$180K 0.24% 35
2020
Q3
$203K Hold
2,568
0.14% 38
2020
Q2
$189K Buy
+2,568
New +$193K 0.14% 37
2020
Q1
Sell
-2,568
Closed -$222K 37
2019
Q4
$222K Hold
2,568
0.15% 37
2019
Q3
$206K Hold
2,568
0.15% 39
2019
Q2
$205K Hold
2,568
0.14% 40
2019
Q1
$204K Buy
+2,568
New +$192K 0.15% 42
2016
Q2
Sell
-210
Closed -$11K 59
2016
Q1
$11K Hold
210
0.01% 52
2015
Q4
$11K Hold
210
0.01% 52
2015
Q3
$11K Buy
+210
New +$11.2K 0.01% 53
2014
Q3
Sell
-524
Closed -$28K 57
2014
Q2
$28K Buy
+524
New +$28.6K 0.05% 47

Other funds holding MRK

Marshall & Sullivan's MRK Position: Q3 2025 in Review

Marshall & Sullivan sold out of Merck (MRK) in Q3 2025, closing a stake of 2,450 shares — an estimated $194K sold.

Marshall & Sullivan first reported a position in MRK in Q2 2014 and held it in 25 quarters. The position peaked at $323K in Q1 2024. 3,310 funds tracked by Wall St. Rank hold MRK as of Q3 2025.

  • Marshall & Sullivan reported no remaining Merck position as of Q3 2025 after selling out during the quarter.
  • Marshall & Sullivan sold 2,450 Merck shares in Q3 2025, an estimated $194K.
  • Marshall & Sullivan first reported a position in Merck in Q2 2014 and held it in 25 quarters.
  • Marshall & Sullivan's Merck position peaked at $323K in Q1 2024.
  • 3,310 funds tracked by Wall St. Rank held Merck as of Q3 2025.

Based on Marshall & Sullivan's 13F filing for Q3 2025, filed 15 Oct 2025.